Ballard Announces 150M-kilometer Milestone

 Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) today announced the Company's proton exchange membrane (PEM) fuel cells have now powered Fuel Cell Electric Vehicles – or FCEVs – in commercial Heavy

 Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) today announced the Company’s proton exchange membrane (PEM) fuel cells have now powered Fuel Cell Electric Vehicles – or FCEVs – in commercial Heavy and Medium-Duty Motive vehicles for an industry-leading total of more than 150 million kilometers. This is roughly equivalent to circling the Earth over 3,700 times. To reach this milestone, Ballard fuel cells powered over 3,800 buses and trucks, providing zero-emission mobility solutions in approximately 15 countries around the world.

Mr. Randy MacEwen, President and Chief Executive Officer said, “At Ballard, we are designing our PEM fuel cell engines for heavy-duty mobility applications where zero emissions, reliability, and durability are key differentiators for end-user total cost of ownership. We continue to set the industry benchmark for PEM fuel cell performance in our target markets. The accumulated distance driven by FCEVs powered by our technology underlines Ballard’s customer focus and commitment to reliable service and high uptime.”

Mr. MacEwen continued, “We achieve this industry milestone at a time when we are seeing growing customer interest in the adoption of hydrogen fuel cells in our key mobility verticals of bus, truck, rail, and marine, as well as off-highway and stationary power applications. Our learnings from real-world experience will continue to help us optimize our products from a total cost of ownership perspective and deliver products to meet zero-emissions targets without disrupting existing operating practices, including range, payload, and refueling time.”

Total
0
Shares
Related Posts
Read More

Investor Fear Eases As US Stocks Rise Following Economic Reports

The CNN Money Fear and Greed index moved to the "Fear" zone on Thursday. U.S. stocks closed higher, with the Dow Jones Industrial Average gaining over 100 points on Thursday. Investors await the release of the personal consumption expenditures price index, which is Federal Reserve’s preferred inflation gauge, on Friday.

ACN

Read More

AstraZeneca Announced Enhertu Showed Clinically Meaningful And Durable Responses Across Multiple HER2-Expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial

Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients.

AZN